Aclaris Therapeutics, Inc. (ACRS) — Stock Score Summary

Aclaris Therapeutics, Inc. (ACRS) has a MoatMap StockRank of 41/100 based on Quality (29/100), Value (34/100), and Momentum (65/100) factor scores. The current signal is HOLD. Aclaris Therapeutics is a clinical-stage biopharmaceutical company with no commercialized products of scale, negative cash flows, and no structural moat.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapies for immuno-inflammatory diseases. The company leverages its proprietary KINect™ platform to identify and advance drug candidates that selectively modulate specific immune pathways, with a current focus on dermatology and rheumatology. Aclaris aims to address significant unmet medical needs with potential first-in-class or best-in-class treatments.

Key Financial Metrics

Price$4.34
Market Cap$638M
P/E (Forward)-5.68
Price/Book4.58
Return on Equity-48.4%
Return on Invested Capital-56.2%
Debt/Equity1.38
Gross Margin0.0%
Operating Margin-1111.8%
Revenue Growth37.2%
Free Cash Flow$-32M

Aclaris Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Aclaris Therapeutics, Inc.’s (ACRS) StockRank?
MoatMap’s StockRank for Aclaris Therapeutics, Inc. (ACRS) is 41/100, with a Hold signal. It is a composite of Quality (29), Value (34), and Momentum (65) factor ranks across MoatMap’s 19,000+ stock universe.
Does Aclaris Therapeutics, Inc. have an economic moat?
Aclaris Therapeutics, Inc. (ACRS) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Aclaris Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Aclaris Therapeutics, Inc. (ACRS) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Aclaris Therapeutics, Inc. in?
Aclaris Therapeutics, Inc. (ACRS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksACRS deep dive reportAI ChampionsHow we score stocksSense-check another stock